Biotechnology Advances Impact Factor

The first useful signal is that Biotechnology Advances is not a general-interest catch-all. A 12.5 JIF combined with a 15.7 five-year JIF says the journal's better papers keep working as durable reference pieces, which is exactly what strong review-led biotechnology journals are supposed to do.

The second signal is that the number is relatively clean. The JIF without self-cites is 12.1, which is close to the reported JIF. That means the headline figure is not mainly an internal-citation story.

The third signal is article type. This is a review-heavy journal. That matters because citation strength here reflects field-shaping synthesis, platform framing, and translational usefulness more than it reflects a traditional primary-data prestige ladder.

The Scopus impact score of 13.90, SJR of 2.662, and h-index of 260 reinforce that this is a durable, high-trust review venue rather than a one-cycle spike.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 13.54 in 2023 to 13.90 in 2024. That matters because it suggests the journal is holding its authority after a hotter 2021 to 2022 period instead of sliding back toward its earlier baseline.

The broader pattern is healthy: high long-run citation persistence with some cooling from the peak years, not a collapse in relevance.

The common mistake is to assume that because this is a high-impact biotechnology title, any review about a biotechnology-adjacent topic belongs here.

That is not how the journal is framed publicly. Biotechnology Advances is strongest when the manuscript helps readers understand where biotechnology is actually moving, what the real constraints are, and why the application logic is credible. Editors are usually screening for:

• a topic that matters beyond one narrow subfield
• a clear platform, translational, industrial, environmental, or therapeutic angle
• synthesis that explains bottlenecks and decision points, not just literature volume
• a manuscript that reads like biotechnology, not basic biology with an applications paragraph

That means the metric confirms status. It does not widen the manuscript's real scope.

In our pre-submission review work on manuscripts targeting Biotechnology Advances, the repeat problem is false breadth.

Authors often bring a competent review or perspective that covers a lot of papers, but it still does not answer the real editorial question: what is the biotechnology decision, bottleneck, or platform shift the review helps the field see more clearly?

In our pre-submission review work on manuscripts targeting Biotechnology Advances, four failure patterns recur.

The topic is broad in surface area but narrow in payoff. The review covers a large literature, but the practical biotechnology consequence is still vague.

The manuscript reads like basic biology. This is common when the application case arrives late or feels bolted on.

The review summarizes instead of synthesizing. Editors want framing, comparison, and bottleneck logic, not a long list of studies.

The industrial or translational angle is claimed rather than demonstrated. If the deployment logic is hand-wavy, the fit gets weaker fast.

If that sounds familiar, a Biotechnology Advances submission readiness check is usually more useful than another round of sentence cleanup.

The impact factor does not tell you whether the review has enough field-scale usefulness, whether the topic really carries platform consequence, or whether the manuscript is synthesizing the literature rather than merely summarizing it.

That is where most mismatches happen. The metric places the journal. It does not create editorial breadth that is not already in the manuscript.